Cover Image
市場調查報告書

偏頭痛:開發中產品分析

Migraine - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232767
出版日期 內容資訊 英文 184 Pages
訂單完成後即時交付
價格
Back to Top
偏頭痛:開發中產品分析 Migraine - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 184 Pages
簡介

偏頭痛的特徵是不斷重複嚴重襲來的頭痛,通常都只有半邊頭陣陣發疼。這樣的頭痛多半會伴隨著噁心,嘔吐,畏光或畏聲等對光聲過度反應。症狀有出聲障礙、臉或手臂、臂膀感到刺痛、日常身體動作惡化等。

本報告提供血脂異常症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您夾雜了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。。

簡介

偏頭痛概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9308IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine - Pipeline Review, H1 2017, provides an overview of the Migraine (Central Nervous System) pipeline landscape.

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Migraine - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 13, 14, 14, 21, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Migraine - Overview
  • Migraine - Therapeutics Development
  • Migraine - Therapeutics Assessment
  • Migraine - Companies Involved in Therapeutics Development
  • Migraine - Drug Profiles
  • Migraine - Dormant Projects
  • Migraine - Discontinued Products
  • Migraine - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Migraine, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Migraine - Pipeline by 4P Therapeutics LLC, H1 2017
  • Migraine - Pipeline by Achelios Therapeutics Inc, H1 2017
  • Migraine - Pipeline by Acorda Therapeutics Inc, H1 2017
  • Migraine - Pipeline by Alder Biopharmaceuticals Inc, H1 2017
  • Migraine - Pipeline by Allergan Plc, H1 2017
  • Migraine - Pipeline by Amgen Inc, H1 2017
  • Migraine - Pipeline by Aralez Pharmaceuticals Inc, H1 2017
  • Migraine - Pipeline by Astellas Pharma Inc, H1 2017
  • Migraine - Pipeline by Avanir Pharmaceuticals Inc, H1 2017
  • Migraine - Pipeline by Biofrontera AG, H1 2017
  • Migraine - Pipeline by BioHealthonomics Inc, H1 2017
  • Migraine - Pipeline by Charleston Laboratories Inc, H1 2017
  • Migraine - Pipeline by Corium International Inc, H1 2017
  • Migraine - Pipeline by Eli Lilly and Company, H1 2017
  • Migraine - Pipeline by Impel NeuroPharma Inc, H1 2017
  • Migraine - Pipeline by InKemia IUCT Group SA, H1 2017
  • Migraine - Pipeline by InStar Technologies AS, H1 2017
  • Migraine - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Migraine - Pipeline by Klaria Pharma Holding AB, H1 2017
  • Migraine - Pipeline by Medestea Research & Production SpA, H1 2017
  • Migraine - Pipeline by Merck & Co Inc, H1 2017
  • Migraine - Pipeline by Monosol Rx LLC, H1 2017
  • Migraine - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
  • Migraine - Pipeline by Promius Pharma LLC, H1 2017
  • Migraine - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Migraine - Pipeline by Revance Therapeutics Inc, H1 2017
  • Migraine - Pipeline by Shin Nippon Biomedical Laboratories Ltd, H1 2017
  • Migraine - Pipeline by Suda Ltd, H1 2017
  • Migraine - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
  • Migraine - Pipeline by TheraJect Inc, H1 2017
  • Migraine - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017
  • Migraine - Pipeline by Trevena Inc, H1 2017
  • Migraine - Pipeline by Trigemina Inc, H1 2017
  • Migraine - Pipeline by TrioxBio Inc, H1 2017
  • Migraine - Pipeline by Vertex Pharmaceuticals Inc, H1 2017
  • Migraine - Pipeline by Xenon Pharmaceuticals Inc, H1 2017
  • Migraine - Pipeline by Zosano Pharma Corp, H1 2017
  • Migraine - Dormant Projects, H1 2017
  • Migraine - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Migraine - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Migraine - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Migraine - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Migraine, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top